Moving towards a Treatable Traits model of care for the management of obstructive airways diseases

Agustí, Àlvar; Barnes, Neil; Cruz, Álvaro Augusto; Gibson, Péter G.; Heaney, Liam G.; Inoue, Hiromasa; Leather, David; Martínez, Fernando J.; McDonald, Vanessa M.; Oppenheimer, John; Papi, Alberto; Pavord, Ian; Thomas, Mike; Walker, Samantha; Yates, Louisa

doi:10.1016/j.rmed.2021.106572

Cited by 36 publications

(31 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our service achieves this using a Treatable Traits approach. Treatable Traits is a model of care that facilitates an assessment of individual patients to identify traits according to the airway, behavioural/risk factor and comorbidity domains [ 10 , 25 , 30 , 31 ]. Once traits are identified an individualised treatment plan is developed to deliver targeted treatments according to the identified traits.…”

Section: The Newcastle Multidisciplinary Modelmentioning

confidence: 99%

Multidisciplinary care in chronic airway diseases: the Newcastle model

McDonald

Gibson²

2022

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

Chronic airway diseases including, asthma and chronic obstructive pulmonary disease (COPD) are prevalent and high burden conditions with the majority of patients successfully managed in the primary care setting. However, some patients with more complex disease such as difficult-to-treat or severe asthma, or complex COPD, tertiary care is required. This review provides an overview of the successful tertiary care multidisciplinary respiratory service that operates in Newcastle, New South Wales, Australia, which has been integrated into the tertiary care outpatient clinics for almost three decades. The service is multifaceted in terms of the clinical care it provides, and includes an “Inpatient service”, “Asthma Management Service”, “Difficult Airway Clinic”, “Drug Administration Clinic”, “Rapid Access Clinic”, “Pulmonary Rehabilitation” and has an integrated research programme. The core of the multidisciplinary approach to airway diseases is a person-centred model of care, the “Treatable Traits” approach. The staffing of this service comprises of consultant physicians, respiratory advanced trainees, respiratory scientists, physiotherapists, speech pathologists, nurse specialists and a nurse consultant. Patients that present to this service undergo an initial assessment and clinical review by team members, synthesis of relevant data, and development of a diagnosis and management plan. Based on this review specific interventions are determined according to the traits identified. Overtime the service has evolved to accommodate the increasing numbers of patients requiring access to the “Difficult Airways Clinic” assessment and therapies. This has been facilitated by partnered with the Centres of Excellence in Severe Asthma and Treatable Traits to develop educational and practice management tools.

show abstract

Section: The Newcastle Multidisciplinary Modelmentioning

confidence: 99%

Multidisciplinary care in chronic airway diseases: the Newcastle model

McDonald

Gibson²

2022

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Treatable Traits is a precision medicine approach that has been developed and proposed for the management of obstructive airway diseases, including asthma. [8][9][10] It is achieving global support in the international guidelines for chronic obstructive pulmonary disease (COPD) 11 and severe asthma, 12 as well as being the subject of major symposia at national and international respiratory meetings. A PubMed search (16 December 2020) using the term "treatable traits" identified 192 publications since 2016, the date of the first publication proposing the term for the approach.…”

mentioning

confidence: 99%

“…A PubMed search (16 December 2020) using the term "treatable traits" identified 192 publications since 2016, the date of the first publication proposing the term for the approach. 8 Treatable Traits should be considered as a model of care, 10 where a patient undergoes a multidimensional assessment to identify clinically important and treatable problems (traits). A specific treatable trait is defined as a "therapeutic target identified by phenotypes or endotypes through a validated biomarker".…”

mentioning

confidence: 99%

“…Treatable Traits should be considered as a model of care, 10 where a patient undergoes a multidimensional assessment to identify clinically important and treatable problems (traits). A specific treatable trait is defined as a “therapeutic target identified by phenotypes or endotypes through a validated biomarker” 9 .…”

mentioning

confidence: 99%

“…Treatable Traits is a precision medicine approach that has been developed and proposed for the management of obstructive airway diseases, including asthma 8‐10 . It is achieving global support in the international guidelines for chronic obstructive pulmonary disease (COPD) 11 and severe asthma, 12 as well as being the subject of major symposia at national and international respiratory meetings.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Treatable traits in asthma: moving beyond diagnostic labels

McDonald

Gibson

2022

Medical Journal of Australia

View full text Add to dashboard Cite

Treatable traits in asthma: moving beyond diagnostic labels A precision medicine approach to asthma places the patient at the centre of their care A sthma is a common inflammatory disease, affecting over 300 million people worldwide, 1 including one in nine Australian adults. 2 Asthma imposes a major burden on the health care system, on patients, and within society. 3 In the late 20th century and the early 2000s, there were major improvements in asthma outcomes, largely because of the introduction of inhaled corticosteroids to treat eosinophilic airway inflammation, and asthma self-management education initiatives. 4 These improvements in asthma outcomes are now being lost. Hospitalisations and mortality from asthma have begun to rise as adoption of new assessment techniques and biomarkers into practice stagnates, and we experience sluggish development of new drug discovery in comparison to other diseases. 4 Asthma deaths have risen in Australia, the United Kingdom and the United States, 4 with at least one person in Australia dying every day from asthma. 2

show abstract